The intra-articular steroid preparation methylprednisolone acetate is as effective as triamcinolone acetonide in the treatment of chronic inflammatory arthritis, according to the results of a trial.
Erectile dysfunction may potentially be associated with gout, a new systematic report and meta-analysis reveals. However, the low quality and high degree of heterogeneity among the studies included reduce the certainty of this conclusion.
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.
The rates of herpes zoster (HZ) vaccination may significantly improve with the electronic identification of vaccine eligibility and best practice alert (BPA), according to a quality improvement project based on the pre- and postintervention design.
Despite having no adverse effect, there is no evidence supporting the efficacy of teriparatide for healing fractures, a new meta-analysis reports. However, more high-quality studies are needed to yield more definitive conclusions about its effectiveness.
Bariatric surgery (gastric banding and gastric bypass) may reduce the risk and improve the prognosis of psoriasis and psoriatic arthritis in obese patients, a study from Denmark shows.
Use of tocilizumab—through the intravenous or subcutaneous route and either as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs—carries a low risk of immunogenicity in rheumatoid arthritis, a study has shown.
The risk of sleep disturbances may be higher among patients with rheumatoid arthritis (RA) than among individuals without the disorder, a recent study suggests.
Adequately administered biological therapies, with proper follow-up, do not increase the risk for cancer development in patients with psoriatic arthritis (PsA), an observational study confirms.
Secukinumab is safe and effective for ankylosing spondylitis (AS), producing improvements in AS signs/symptoms that can be maintained through 2 years of continuous therapy and with no new safety issues, according to data from the phase III MEASURE 1 study.